Cara Therapeutics Inc (NASDAQ:CARA) CFO Mani Mohindru sold 4,755 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $17.05, for a total transaction of $81,072.75. Following the completion of the sale, the chief financial officer now owns 22,196 shares of the company’s stock, valued at $378,441.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
NASDAQ CARA traded up $0.10 on Wednesday, hitting $17.03. 2,483,305 shares of the company’s stock traded hands, compared to its average volume of 725,814. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.02. Cara Therapeutics Inc has a 1-year low of $12.19 and a 1-year high of $27.55. The firm’s 50-day moving average price is $21.45 and its two-hundred day moving average price is $21.61. The firm has a market capitalization of $1.04 billion, a PE ratio of -8.27 and a beta of 2.30.
Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. The business had revenue of $5.79 million for the quarter, compared to analyst estimates of $5.56 million. On average, research analysts anticipate that Cara Therapeutics Inc will post -2.55 earnings per share for the current fiscal year.
A number of analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 target price on shares of Cara Therapeutics in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Cara Therapeutics in a research note on Tuesday. BidaskClub upgraded shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. ValuEngine upgraded shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Zacks Investment Research cut shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $27.54.
About Cara Therapeutics
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
See Also: What is FinTech?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.